160 related articles for article (PubMed ID: 38344849)
1. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C
Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
3. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
Mühlenberg T; Falkenhorst J; Schulz T; Fletcher BS; Teuber A; Krzeciesa D; Klooster I; Lundberg M; Wilson L; Lategahn J; von Mehren M; Grunewald S; Tüns AI; Wardelmann E; Sicklick JK; Brahmi M; Serrano C; Schildhaus HU; Sievers S; Treckmann J; Heinrich MC; Raut CP; Ou WB; Marino-Enriquez A; George S; Rauh D; Fletcher JA; Bauer S
J Clin Oncol; 2024 Apr; 42(12):1439-1449. PubMed ID: 38408285
[TBL] [Abstract][Full Text] [Related]
4. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S; George S; von Mehren M; Heinrich MC
Front Oncol; 2021; 11():672500. PubMed ID: 34322383
[TBL] [Abstract][Full Text] [Related]
5. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.
Zhou S; Abdihamid O; Tan F; Zhou H; Liu H; Li Z; Xiao S; Li B
Cell Commun Signal; 2024 Feb; 22(1):153. PubMed ID: 38414063
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
[TBL] [Abstract][Full Text] [Related]
7. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
9. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract][Full Text] [Related]
10. New insights into the clinical management of advanced gastrointestinal stromal tumors.
Italiano A
Expert Opin Pharmacother; 2021 Mar; 22(4):439-447. PubMed ID: 33307872
[TBL] [Abstract][Full Text] [Related]
11. Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.
Liu WZ; Du YQ; Shen Q; Tao KX; Zhang P
J Dig Dis; 2023 Sep; ():. PubMed ID: 37706279
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
Senchak J; Ahr K; von Mehren M
Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
[TBL] [Abstract][Full Text] [Related]
13. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Serrano C; Bauer S
Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
[TBL] [Abstract][Full Text] [Related]
14. [Management of gastrointestinal stromal tumors].
Watson S; Bonnet C
Rev Prat; 2024 May; 74(5):537-541. PubMed ID: 38833239
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor.
Etherington MS; Hanna AN; Medina BD; Liu M; Tieniber AD; Kwak HV; Tardy KJ; Levin L; Do KJ; Rossi F; Zeng S; DeMatteo RP
Cancer Immunol Res; 2024 Jan; 12(1):107-119. PubMed ID: 37922405
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).
De Sutter L; Wozniak A; Verreet J; Vanleeuw U; De Cock L; Linde N; Drechsler C; Esdar C; Sciot R; Schöffski P
Clin Cancer Res; 2023 Aug; 29(15):2859-2868. PubMed ID: 37223931
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
18. Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
Grunewald S; Klug LR; Mühlenberg T; Lategahn J; Falkenhorst J; Town A; Ehrt C; Wardelmann E; Hartmann W; Schildhaus HU; Treckmann J; Fletcher JA; Jung S; Czodrowski P; Miller S; Schmidt-Kittler O; Rauh D; Heinrich MC; Bauer S
Cancer Discov; 2021 Jan; 11(1):108-125. PubMed ID: 32972961
[TBL] [Abstract][Full Text] [Related]
19. Preclinical model-based evaluation of Imatinib resistance induced by
Zhao Q; Zhang C; Qi C; Yang J; Chen Y; Ge S; Shen L; Gao J; Li J
Am J Transl Res; 2021; 13(12):13608-13624. PubMed ID: 35035701
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
[Next] [New Search]
